Physician profile
Reshma Ramakrishnan
NPI 1346528262
$5,771.38
in general payments reported to CMS, 2019-2025
52 companies · $996 in 2025
The $996 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $803 · 2020: $242 · 2021: $436 · 2022: $959 · 2023: $1,088 · 2024: $1,248 · 2025: $996.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,331.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,331.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $825.29 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $580.83 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Sanofi-Aventis U.S. LLC | $334.89 | 2019-2025 | |
| Amgen INC. | $310.54 | 2019-2025 | Tepezza, Repatha, Evenity |
| Abbott Laboratories | $271.95 | 2019-2025 | Freestyle Libre 3 |
| Abbvie INC. | $202.65 | 2019-2025 | |
| Corcept Therapeutics | $195.34 | 2023-2025 | Korlym |
| Astrazeneca Pharmaceuticals LP | $185.08 | 2019-2022 | |
| Medtronic Minimed, INC. | $178.34 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $176.31 | 2022-2025 | |
| Mannkind Corporation | $167.62 | 2019-2024 | Afrezza |
| Radius Health, INC. | $167.35 | 2019-2025 | Tymlos |
| Amneal Pharmaceuticals LLC | $154.20 | 2022-2025 | Unithroid |
| Ascendis Pharma Endocrinology INC | $148.91 | 2023-2025 | Yorvipath |
| Medtronic, INC. | $136.18 | 2021-2025 | Minimed 780g |
Show all 52 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $125.90 | 2021-2024 | Gvoke Hypopen, Recorlev |
| Alvogen INC | $109.07 | 2022-2025 | Teriparatide |
| Alexion Pharmaceuticals, INC. | $108.52 | 2019-2025 | Strensiq |
| Dexcom, INC. | $104.64 | 2019-2025 | Dexcom G6 Transmitter |
| Tandem Diabetes Care, INC. | $99.75 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Ultragenyx Pharmaceutical INC. | $99.19 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $94.82 | 2021-2024 | Jardiance, Tradjenta |
| Neurocrine Biosciences, INC. | $90.56 | 2024-2025 | |
| Lifescan, INC. | $81.52 | 2019-2023 | |
| Becton, Dickinson and Company | $76.06 | 2019-2022 | |
| Insulet Corporation | $65.97 | 2019-2025 | Omnipod |
| Cequr Corporation | $62.98 | 2022-2025 | Cequr Simplicity |
| Merck Sharp & Dohme LLC | $56.61 | 2019-2022 | |
| Beta Bionics, INC. | $54.26 | 2023-2024 | Ilet Bionic Pancreas |
| Acella Pharmaceuticals, LLC | $37.86 | 2025 | NP Thyroid 60 |
| Ibsa Pharma INC. | $32.65 | 2020-2025 | Flector, Licart, Tirosint |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.49 | 2019 | |
| Janssen Pharmaceuticals, INC | $29.90 | 2019 | |
| Amryt Pharma Holdings LTD | $29.81 | 2022-2023 | Mycapssa |
| Amarin Pharma, INC. | $29.39 | 2021 | |
| Tolmar, INC. | $28.35 | 2024 | |
| Currax Pharmaceuticals LLC | $27.58 | 2021-2023 | Nexlizet, Contrave, Nexletol |
| Ipsen Biopharmaceuticals, INC | $23.45 | 2022 | |
| Kyowa Kirin, INC. | $22.91 | 2023 | Crysvita |
| Ascensia Diabetes Care US INC. | $22.50 | 2024 | |
| Eusa Pharma (US) LLC | $21.02 | 2022 | |
| Recordati_rare_diseases_inc. | $21.02 | 2022 | |
| Nevro Corp. | $17.87 | 2022 | |
| Astellas Pharma US INC | $17.71 | 2024 | Veozah |
| Horizon Therapeutics Plc | $16.88 | 2019 | |
| Eisai INC. | $15.34 | 2019 | |
| Shire North American Group INC | $15.11 | 2019 | |
| Clarus Therapeutics INC. | $14.72 | 2021 | |
| Rgh Enterprises LLC | $13.71 | 2025 | |
| Embecta Corp. | $12.69 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Pfizer INC. | $12.64 | 2022 | |
| Theracosbio, LLC | $10.45 | 2024 | Brenzavvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reshma Ramakrishnan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.